Alcon has awarded two accounts to StrikeForce Communications, including global strategic and creative responsibilities for I-Caps, a line of ocular nutrition products aimed at delaying the progress of age related macular degeneration, and for OTC dry eye therapy Systane. The New York-based shop also recently won an assignment for Orexigen Theraeutics‘ obesity drug, which is under FDA review.
Makovsky + Company has been retained by Neoprobe Corp., for its strategic communications and investor relations program as the Dublin, Ohio-based firm, which makes surgical oncology products, prepares for the commercialization of Lymphoseek and the launch of a RIGS clinical development program.
